Literature DB >> 10332049

Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line.

T Minko1, P Kopecková, J Kopecek.   

Abstract

The influence of free and N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound adriamycin (ADR) on the induction of multidrug resistance in the A2780 human ovarian carcinoma cell line was studied in vitro. It was found that chronic exposure to free ADR led to an increase in resistance to ADR and Taxol and overexpression of the MDR1 gene. No significant changes in the expression of the MRP gene were found during adaptation to free ADR. In addition to MDR1 gene-encoded multidrug resistance, a significant increase in the resistance against ADR was found before the overexpression of the MDR1 gene was measurable. This non-P-glycoprotein resistance does not appear to be connected with MRP gene-encoded resistance. During adaptation to free ADR, changes in cellular metabolism such as increased rate of glucose uptake, oxidation and glycolysis were detected. Adapted sensitive A2780 cells expressed the MDR1 gene and possessed almost the same decreased sensitivity toward ADR as the ADR-resistant human ovarian carcinoma A2780/AD cells. However, they significantly differed in proliferation rate, cellular metabolism and MRP gene expression. On the contrary, multidrug resistance was not induced after repeated exposure of sensitive A2780 cells to HPMA copolymer-bound adriamycin. The cells did not express the MDR1 gene, the expression of the MRP gene was partially inhibited, and the resistance against Taxol was decreased. Differences were also observed in metabolic changes. In summary, the data indicate that, contrary to free ADR, HPMA copolymer-bound ADR does not induce multidrug resistance in A2780 cell culture after repeated exposure.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10332049     DOI: 10.1016/s0168-3659(98)00186-2

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  27 in total

Review 1.  Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.

Authors:  Xiaowei Dong; Russell J Mumper
Journal:  Nanomedicine (Lond)       Date:  2010-06       Impact factor: 5.307

2.  Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells.

Authors:  T Minko; P Kopecková; J Kopecek
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

3.  Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles.

Authors:  Carlee E Ashley; Eric C Carnes; Genevieve K Phillips; Paul N Durfee; Mekensey D Buley; Christopher A Lino; David P Padilla; Brandy Phillips; Mark B Carter; Cheryl L Willman; C Jeffrey Brinker; Jerri do Carmo Caldeira; Bryce Chackerian; Walker Wharton; David S Peabody
Journal:  ACS Nano       Date:  2011-06-07       Impact factor: 15.881

Review 4.  Design of smart HPMA copolymer-based nanomedicines.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

Review 5.  Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.

Authors:  Darren Lars Stirland; Joseph W Nichols; Seiji Miura; You Han Bae
Journal:  J Control Release       Date:  2013-10-02       Impact factor: 9.776

6.  Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma.

Authors:  Michiro Susa; Arun K Iyer; Keinosuke Ryu; Edwin Choy; Francis J Hornicek; Henry Mankin; Lara Milane; Mansoor M Amiji; Zhenfeng Duan
Journal:  PLoS One       Date:  2010-05-24       Impact factor: 3.240

7.  Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?

Authors:  Maha Saad; Olga B Garbuzenko; Elizabeth Ber; Pooja Chandna; Jayant J Khandare; Vitaly P Pozharov; Tamara Minko
Journal:  J Control Release       Date:  2008-06-25       Impact factor: 9.776

8.  Preparation, drug release, and cell growth inhibition of a gelatin: doxorubicin conjugate.

Authors:  Darren C Wu; Christopher R Cammarata; Hyun Joo Park; Brian T Rhodes; Clyde M Ofner
Journal:  Pharm Res       Date:  2013-05-18       Impact factor: 4.200

Review 9.  Biological rationale for the design of polymeric anti-cancer nanomedicines.

Authors:  Yan Zhou; Jindřich Kopeček
Journal:  J Drug Target       Date:  2012-09-26       Impact factor: 5.121

10.  Enhanced antitumor activity of combinations of free and HPMA copolymer-bound drugs.

Authors:  J Hongrapipat; P Kopecková; S Prakongpan; J Kopecek
Journal:  Int J Pharm       Date:  2007-09-22       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.